REGN
Closed
Regeneron Pharmaceuticals Inc
534.91
+9.91 (+1.89%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 525.
Day's Range: 521. - 548.035
Send
sign up or login to leave a comment!
When Written:
823.76
Regeneron Pharmaceuticals Inc. is an American biotechnology company that develops and commercializes medicines for the treatment of serious medical conditions. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Regeneron is known for its innovative approach to drug development, including the use of genetically modified mice to create humanized antibodies for therapeutic use. The company has developed several successful drugs, including Eylea (a treatment for age-related macular degeneration), Dupixent (a treatment for atopic dermatitis and asthma), and Libtayo (a treatment for certain types of cancer).
Regeneron has partnerships with several major pharmaceutical companies, including Sanofi, Bayer, and Roche. The company has also been involved in the development of treatments for COVID-19, including the monoclonal antibody cocktail used to treat former President Donald Trump.
As of 2021, Regeneron has over 9,000 employees and a market capitalization of over $70 billion.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Regeneron is known for its innovative approach to drug development, including the use of genetically modified mice to create humanized antibodies for therapeutic use. The company has developed several successful drugs, including Eylea (a treatment for age-related macular degeneration), Dupixent (a treatment for atopic dermatitis and asthma), and Libtayo (a treatment for certain types of cancer).
Regeneron has partnerships with several major pharmaceutical companies, including Sanofi, Bayer, and Roche. The company has also been involved in the development of treatments for COVID-19, including the monoclonal antibody cocktail used to treat former President Donald Trump.
As of 2021, Regeneron has over 9,000 employees and a market capitalization of over $70 billion.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








